Details for Patent: 11,833,292
✉ Email this page to a colleague
Which drugs does patent 11,833,292 protect, and when does it expire?
Patent 11,833,292 protects BREZTRI AEROSPHERE and is included in one NDA.
This patent has twenty-five patent family members in thirteen countries.
Summary for Patent: 11,833,292
| Title: | Drug delivery systems and related methods |
| Abstract: | Systems and methods for isolating and/or desiccating a portion of a drug delivery tract of a drug delivery apparatus to reduce water vapor content therein are provided. For example, there is provided a metered dose inhaler for delivering aerosolized medicament or other matter to a user. The aerosolized medicament or other matter may be discharged from a discharge passageway within the inhaler into an inhalation passageway for inhalation by a user, and the inhaler may comprise a seal member operative to selectively isolate the discharge passageway from the inhalation passageway and external environment during inactivity. The inhaler may further comprise a desiccant material arranged to withdraw moisture from the isolated discharge passageway. In other instances, desiccant material may be arranged to withdraw moisture from the discharge passageway of the inhaler without isolating the discharge passage during inactivity. |
| Inventor(s): | Matthew Ferriter, Denny Himel, Brian Foster, Michael L. King, Dan Deaton, Fred Hamlin, Jill Sherwood, Sarvajna Kumar Dwivedi, Robert V. Sheehy, Jr. |
| Assignee: | Pearl Therapeutics Inc |
| Application Number: | US16/754,585 |
|
Patent Claim Types: see list of patent claims | Formulation; Delivery; Device; |
Drugs Protected by US Patent 11,833,292
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Astrazeneca Ab | BREZTRI AEROSPHERE | budesonide; formoterol fumarate; glycopyrrolate | AEROSOL, METERED;INHALATION | 212122-001 | Jul 23, 2020 | RX | Yes | Yes | 11,833,292 | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| Astrazeneca Ab | BREZTRI AEROSPHERE | budesonide; formoterol fumarate; glycopyrrolate | AEROSOL, METERED;INHALATION | 212122-002 | Apr 27, 2026 | RX | Yes | Yes | 11,833,292 | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 11,833,292
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2018347970 | ⤷ Start Trial | |||
| Australia | 2024205820 | ⤷ Start Trial | |||
| Brazil | 112020006696 | ⤷ Start Trial | |||
| Canada | 3078209 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
